| Lost password
369 users onlineYou are not loggend in.  Login
Curcumin treatment for DC
 1 2 3
 1 2 3
01/21/2005 23:50
Michael

not registered

01/21/2005 23:50
Michael

not registered

TGF-beta 2 & Dup~sq~s

An article relating to TGF-beta 2 and Dupuytren's appeared recently on PubMed - the following is the abstract. The upshot is that inhibiting TGF-beta 2 might not have any effect on Dup's progression:

'Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-β2'

Raymond Tse,1,4 Jeffrey Howard,1,2,4 Yan Wu,1,4 and Bing Siang Gan1,2,3,4

Background

Dupuytren's disease (DD) is a debilitating fibro-proliferative disorder of the hand characterized by the appearance of fibrotic lesions (nodules and cords) leading to flexion contractures of the fingers and loss of hand function. Although the molecular mechanism of DD is unknown, it has been suggested that transforming growth factor-β2 (TGF-β2) may play an important role in the underlying patho-physiology of the disease. The purpose of this study was to further explore this hypothesis by examining the effects of TGF-β2 on primary cell cultures derived from patient-matched disease and normal palmar fascia tissue using a three-dimensional collagen contraction assay.

Methods

Fibroblast-populated collagen lattice (FPCL) contraction assays using primary cell cultures derived from diseased and control fascia of the same DD patients were studied in response to exogenous TGF-β2 and neutralizing anti-TGF-β2 antibodies.

Results

Contraction of the FPCLs occurred significantly faster and to a greater extent in disease cells compared to control cells. The addition of TGF-β2 enhanced the rate and degree of collagen contraction in a dose-dependent fashion for both control and diseased cells. Neutralizing anti-TGF-β2 antibodies abolished exogenous TGF-β2 stimulated collagen contraction, but did not inhibit the enhanced basal collagen contraction activity of disease FPCL cultures.

Conclusions

Although exogenous TGF-β2 stimulated both disease and control FPCL contraction, neutralizing anti-TGF-β2 antibodies did not affect the elevated basal collagen contraction activity of disease FPCLs, suggesting that the differences in the collagen contraction activity of control and disease FPCL cultures are not due to differences in the levels of endogenous TGF-β2 activity.

02/06/2005 23:50
Michael

not registered

02/06/2005 23:50
Michael

not registered

My experience with curcumin


Well, Nypon, you made such a plausible case for curcumin that I decided to try it out. I've been taking at least 1800 mg/day of curcumin + bioperine starting around the beginning of Nov. 2004 until the present day.

Results are: I don't think curcumin made any difference in the progression of my dup's. Whether the growth was slowed from what it otherwise would have been, of course it's impossible to say. But I can definitely say that it didn't stop the growth.

That's not to say that curcumin isn't worthwhile taking for other reasons. I've read some of the studies, and there is pretty solid evidence that curcumin has anti-carciogenic properties for colon cancer and perhaps other cancers as well.

03/20/2005 23:45
toM

not registered

03/20/2005 23:45
toM

not registered

For those interested in Turmeric

A recent article in the Journal of Neuroinflammation at http://www.jneuroinflammation.com/content/2/1/8 discusses curcumin (believed to be the primary active component of turmeric) and alzheimers.

12/16/2005 23:28
toM

not registered

12/16/2005 23:28
toM

not registered

Can Curcumin Help Prevent Alzheimer~sq~s Disease?

Hi, apologize for this off topic posting but feel the news may be of interest to many.

http://www.alzheimersupport.com/library/showarticle.cfm/id/2173

Research: Can Curcumin Help Prevent Alzheimer's Disease?
alzheimersupport.com

01-17-2005

Curcumin, the yellow pigment in curry spice, is to be investigated for its potential in prevention of Alzheimer’s disease after tests on mice found it to be more effective than drugs currently being investigated for treatment.

A dietary staple of India, where Alzheimer's disease rates are reportedly among the world's lowest, curcumin appears to block and break up brain plaques that cause the disease.

The spice has also been found to correct the cystic fibrosis defect in mice, prevent the onset of alcoholic liver disease and may slow down the blood cancer multiple myeloma as well as multiple sclerosis.

Reporting in the 7 December online edition of the Journal of Biological Chemistry, researchers from the University of California Los Angeles also revealed that curcumin is more effective in inhibiting formation of the protein fragments than many other drugs being tested as Alzheimer's treatments.

The researchers found the low molecular weight and polar structure of curcumin allow it to penetrate the blood-brain barrier effectively and bind to beta amyloid (which form the disease-causing plaques). In earlier studies published during 2001, the same research team found curcumin has powerful antioxidant and anti-inflammatory properties, which scientists believe help ease Alzheimer's symptoms caused by oxidation and inflammation.

The body of research has prompted the UCLA Alzheimer's Disease Research Center (ADRC) to begin human clinical trials to further evaluate its protective and therapeutic effects.

"The prospect of finding a safe and effective new approach to both prevention and treatment of Alzheimer's disease is tremendously exciting," said principal investigator Gregory Cole, professor of medicine and neurology at the David Geffen School of Medicine at UCLA and associate director of the UCLA Alzheimer's Disease Research Center.

"Curcumin has been used for thousands of years as a safe anti-inflammatory in a variety of ailments as part of Indian traditional medicine," Cole added.

"Recent successful studies in animal models support a growing interest in its possible use for diseases of ageing involving oxidative damage and inflammation like Alzheimer's, cancer and heart disease. What we really need, however, are clinical trials to establish safe and effective doses in aging patients."

Alzheimer's disease is the most common form of dementing illness among middle and older adults, affecting more than 4 million Americans and many millions worldwide. The prevalence of Alzheimer's among adults aged 70-79 in India, however, is 4.4 times less than the rate in the United States.

Copyright © 2000/2005 NOVIS. All Rights Reserved.

 1 2 3
 1 2 3
Alzheimer   cmd=Retrieve&db=pubmed&dopt=Abstract&list   turmeric   collagen   loweringcholesterol   jneuroinflammation   uids=1712697&dopt=Abstract   uids=11712783&dopt=Abstract   Curcumin   fibro-proliferative   anti-inflammatory   contraction   uids=8164441&dopt=Abstract   glomerulosclerosis   uids=2825907&dopt=Abstract   dupuytren%20s%20contracture%20uppsala   TGF-beta   Fibroblast-populated   cmd=Retrieve&db=PubMed&list   disease